26 ruling, the California Horse Racing Commission fined trainer John Sadler $5,000 for knowingly bringing a horse into a CHRB stable that had been treated with bisphosphonates within the previous six months.
The ruling, which came after Sadler entered into a settlement agreement with the CHRB, did not specify the horse in question, but Del Mar the managers said on November 27 that it concerns the winner of classified bets Flagstaff . The horse tested positive for bisphosphonates after finishing runner-up in the Santa Anita Sprint Championship Stakes (G2) on September 27, 2020. That race was one of six starts from the race. sprint athletes in 2020.
Racing jurisdictions and sales companies began banning bisphosphonates in 2019 in response to concerns that the drug could be used to mask radiographic evidence of sesamoidosis in sale horses. young goods. The drug is approved by the US Food and Drug Administration in horses 4 years of age and older to repair bone damage in horses with pelvic disease.
Flagstaff, retired this fall by owners Lane’s End Racing and Hronis Racing, was 7 years old, then 6 years old at the time of the 2020 Santa Anita Sprint Championship.
Sadler’s attorney, Darrell Vienna, previously said Flagstaff was treated with Osphos, the trade name for clodronic acid, in 2019. He added that bisphosphonates can persist and then release in the horse’s system. long after treatment.
Management previously disqualified Flagstaff in a ruling issued this June, resulting in the forfeiture of $40,000 in wallet earnings from the 2020 Santa Anita Sprint Championship.
The son of Sightstown won seven out of 22 starts and over $1 million. Earlier this year, he captured the Churchill Downs Stock presented by Ford (G1) on the Kentucky Derby card at Churchill Downs. He last raced on October 2, running again in the Santa Anita Sprint Championship, in which he finished second behind Dr. Schivel .
He was then assigned to the Qatar Racing Breeders’ Cup Sprint (G1) on 6 November in Del Mar before he was dropped from consideration and retired at the end of October.
Friday’s ruling noted Sadler violated rule 1867.1, which specifically restricts the use of bisphosphonates. Mr. Vienna added that he was not cited for drug violations.
Such a breach may have affected an earlier settlement Sadler made with the CHRB in June 2020, in which the regulator had a 45-day 60-day suspension for violations since spring. 2019. That deal on the condition he doesn’t have one. any drug class 1, 2 or 3 positive during the one-year probationary period.
Vienna said the November 26 ruling would not be contested.
“There will be no appeal, no hearing; it’s all done,” he noted.
